Therma Bright Inc V.THRM

RE:RE:RE:RE:THERMA

[wwmeinc]

Separating the "wheat" from the "chafe" on this board....any potential investor with fresh capital should take notice....any company that will not provide a clarification as to the ownership of an asset that forms the 'backbone' of their newly created 50-50 JV partnership....that touts as its main product the asset in question, a testing kit...will deserve the most scrutiny by everybody....good luck to any mgmt team trying to manage/defend their past nr's that will now be called out for ownership clarification....Hope this helps to wake everybody up to the "transparency" being shown here....once you have looked up the definition of the word  'transparency'.  wwmeinc

wwmeinc wrote: Still waiting thrmadmin, for you to provide to all shareholders the patent information regarding the CoviSafe testing kit....either there is a patent granted or there is none...very simple for you to clarify this issue...post the patent number granted....Why are you stalling??????? wwmeinc

https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=CoviSafe&start=1&num=10&type=basic_search&newSearch=0

Query:  Search

No patents found.

Sorry, no patents were found matching your query

Please modify your query and try again. Example queries  and  search language help  are available.

Didn’t find what you’re looking for?  Search all Government of Canada websites.

wwmeinc wrote: Not a word  thrmadmin...not a single peep!!!!  How telling...well as I  said all you have to do is produce the post/link showing the ownership of the patent(s) of the CoviSafe product your JV entity,Torion is developing....I have doubts,real doubts really that Dr.Dea and Dr.Saeid came to any 'agreement' on who developed/owns the technology which is under-pinning the CoviSafe saliva product...wwmeinc

The NRC is investing nearly $1.2 million dollars to support 4 companies working on a solution:

• Deep Biologics Inc. is receiving $300,000 to develop a palm-sized, portable device that detects viral protein of the SARS-CoV-2 virus in saliva, with results in 20 minutes 
• Fourien Inc. is receiving $296,500 to develop a low-cost, disposable point-of-care device for rapid detection of SARS-CoV-2, by detecting viral ribonucleic acid (RNA) in saliva, with results in under 5 minutes
• Metabolic Insights Inc. is receiving $300,000 to adapt an existing device that detects insulin levels in saliva. The new device will detect the presence of the viral protein of SARS-CoV-2 in a small sample of saliva, with results within 15 minutes
• Nicoya Lifesciences Inc. is receiving $299,190 to develop a rapid, low-cost, easy-to-use device, using ELISA, a proven testing technique. This single-use disposable device will detect the SARS-CoV-2 viral protein in a saliva sample, providing lab-quality results in less than 20 minutes

In response to phase 1 of the challenge, these companies will bring their expertise and R&D capabilities to prove feasibility of their solution for a rapid, single-use testing kit that will diagnose individuals affected by COVID-19 within 3 days of the start of their symptoms using a sample, other than a nasopharyngeal swab. If successful with phase 1 of the challenge, these companies could each receive up to $2M to develop a prototype of their proposed solution.

https://nrc.canada.ca/en/support-technology-innovation/industrial-research-assistance-program-innovative-solutions-canada-covid-19-challenge-program

https://deepbiologics.ai/index.php/all

https://ca.linkedin.com/in/deashahinas

wwmeinc wrote: So this is how you want this to go down,eh thrmadmin??? Ok....so be it...until you post or link to the ownership of the patents behind the CoviSafe product, you are developing under the Torion JV ,I will not desist in asking...it is your choice...you came on here to push/peddle your own self-serving agenda not to serve the best interests of shareholders. wwmeinc

0.065cts

https://ca.linkedin.com/in/deashahinas

thrmadmin wrote: We appreciate everyone’s support and patience and emphasize we are on track, as per previous releases, in terms of continuing our discussions with government agencies and advancing our clinical validations.  Although we encourage communication between our shareholders and ourselves, the volume of emails we are receiving will not accelerate the process. 

To be clear, we are on track and will release news at the appropriate time.